logo
Plus   Neg
Share
Email
Comment

Abbott Xience Xpedition Drug Eluting Stent Gets Approval In Japan

Healthcare company Abbott Laboratories (ABT) said Wednesday that it has received approval for its next-generation Xience Xpedition everolimus eluting coronary stent system in Japan. The approval boosts Abbott's efforts to globally expand its drug-eluting stent systems.

The company said that Japan's Ministry of Health, Labor and Welfare approved the Xience Xpedition stent for the treatment of coronary artery disease or CAD, the most common form of heart disease, in Japan. Heart disease is one of the leading causes of death in Japan, accounting for nearly one-third of all deaths in the country.

Abbott noted that the Xience Xpedition's enhanced deliverability, combined with the broadest size matrix in the Japanese market that includes a unique 3.25 mm diameter for more accurate vessel sizing, will help physicians in Japan address a wide range of patients with CAD.

Masahisa Yamane, director, Cardiovascular Division of Saitama Sekishinkai Hospital in Saitama, Japan said, "The deliverability with Xience Xpedition is impressive, helping physicians navigate with ease through complex blockages inside the heart vessels. This approval offers physicians an important new treatment option to address a growing health concern in Japan; we look forward to the positive impact of this product in Japanese patients with coronary heart disease."

Xience Xpedition is currently available in the U.S, Europe, the Middle East and parts of Asia.

In Japan, five Abbott-sponsored trials involving more than 3,000 patients implanted with either Xience V or Xience Prime have been conducted. Several other studies, including investigator-initiated trials, have been conducted since the original launch in Japan of Xience V in 2010.

In Wednesday's regular trading session, ABT is trading at $35.07, up $0.33 or 0.94 percent on a volume of 906,625 shares.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Dish Network Corp. on Wednesday reported a surge in profit for the fourth quarter from last year, reflecting an income tax benefit that helped offset the impact of lower revenues. The latest quarter's results were positively impacted by an income tax benefit of about $1.2 billion due to an adjustment to deferred tax assets and liabilities related to tax reform legislation. Shares of Glencore plc were gaining around 4 percent in the morning trading in London after the producer and marketer of commodities reported Wednesday a significant growth in fiscal 2017 profit on strong higher commodity prices. Chief Executive Officer Ivan Glasenberg said, "Our performance in 2017 was our strongest on record, driven by our leading Marketing and Industrial asset businesses." Shares of Orange SA were gaining around 2 percent in the early morning trading in Paris after the French telecom major reported Wednesday a significant growth in fiscal 2017 profit from continuing operations with revenue growth in most regions, mainly France and Spain. In France, revenue grew for the first time since 2009. Attributable net income, meanwhile, declined on the absence of prior
comments powered by Disqus
Follow RTT